TY - JOUR
T1 - Body composition in Japanese patients with psychiatric disorders
T2 - A cross-sectional study
AU - Kishi, Taro
AU - Okuya, Makoto
AU - Sakuma, Kenji
AU - Otaka, Yohei
AU - Saitoh, Eiichi
AU - Iwata, Nakao
N1 - Publisher Copyright:
© 2021 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsycho Pharmacology.
PY - 2021/3
Y1 - 2021/3
N2 - Aim: This study aimed to investigate body composition in Japanese patients with psychiatric disorders. Methods: A cross-sectional study was conducted to assess the body composition in Japanese patients with psychiatric disorders and healthy controls. InBody470 was used to measure the body composition of the participants. For the primary analysis, measures of body composition between patients and healthy controls were compared. Moreover, the following patient subgroups were also compared with the healthy controls: (a) patients with psychotic disorders only, (b) patients with mood disorders only, (c) patients receiving antipsychotics, (d) patients receiving conventional mood stabilizers, (e) patients receiving antidepressants only but not any antipsychotics and/or mood stabilizers, and (f) patients receiving hypnotics/anxiolytics. Results: This study included 205 individuals (105 patients and 100 healthy controls). It was found that patients had a significantly higher body mass index, waist-hip ratio, body fat mass, and percent body fat compared with the healthy controls. Moreover, significant differences were noted in the waist-hip ratio, body fat mass, and percent body fat between all patient subgroups other than patients receiving conventional mood stabilizers subgroup and healthy controls. Conclusion: This is the first cross-sectional study to examine body composition in Japanese patients with psychiatric disorders. No difference in the skeletal muscle volume was noted although patients had higher body fat than healthy controls. A longitudinal and large cohort study in the future, controlling for medication and diagnosis, will need to determine why body fat is increased in Japanese patients with psychiatric disorders.
AB - Aim: This study aimed to investigate body composition in Japanese patients with psychiatric disorders. Methods: A cross-sectional study was conducted to assess the body composition in Japanese patients with psychiatric disorders and healthy controls. InBody470 was used to measure the body composition of the participants. For the primary analysis, measures of body composition between patients and healthy controls were compared. Moreover, the following patient subgroups were also compared with the healthy controls: (a) patients with psychotic disorders only, (b) patients with mood disorders only, (c) patients receiving antipsychotics, (d) patients receiving conventional mood stabilizers, (e) patients receiving antidepressants only but not any antipsychotics and/or mood stabilizers, and (f) patients receiving hypnotics/anxiolytics. Results: This study included 205 individuals (105 patients and 100 healthy controls). It was found that patients had a significantly higher body mass index, waist-hip ratio, body fat mass, and percent body fat compared with the healthy controls. Moreover, significant differences were noted in the waist-hip ratio, body fat mass, and percent body fat between all patient subgroups other than patients receiving conventional mood stabilizers subgroup and healthy controls. Conclusion: This is the first cross-sectional study to examine body composition in Japanese patients with psychiatric disorders. No difference in the skeletal muscle volume was noted although patients had higher body fat than healthy controls. A longitudinal and large cohort study in the future, controlling for medication and diagnosis, will need to determine why body fat is increased in Japanese patients with psychiatric disorders.
UR - http://www.scopus.com/inward/record.url?scp=85099868682&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099868682&partnerID=8YFLogxK
U2 - 10.1002/npr2.12160
DO - 10.1002/npr2.12160
M3 - Article
C2 - 33506653
AN - SCOPUS:85099868682
SN - 1340-2544
VL - 41
SP - 117
EP - 121
JO - Neuropsychopharmacology reports
JF - Neuropsychopharmacology reports
IS - 1
ER -